Multiple Myeloma Committee Meeting Agenda

Chair: Paul Richardson, MD
Vice-Chair: Philip McCarthy, MD

I. Welcome and Introductions

II. Alliance Studies (Completed and Ongoing)
   a. A061202: Phase I/II Pom/Dex +/- Ixazomib (MLN9708) in Relapsed and Refractory MM (RR MM) – Peter Voorhees
   b. A061402: Solitary Osseous Plasmacytoma – Anuj Mahindra
   c. AFT29: Phase II RVd +/- Dara (the Griffin trial) in Newly Diagnosed (ND) MM – Peter Voorhees, Paul Richardson
   d. CALGB 100104 Phase III and derived studies – Sarah Holstein
   e. Auto/Allo in MM (CALGB 100001; Phase I/II) – Sarah Holstein
   f. IFM/DFCI 2009 Study (Phase III BMT CTN 1304; the Determination trial) – Paul Richardson
   g. AFT15: Phase I/II Ibrutinib + Rd in RR MM – Yvonne Efebera

III. Alliance Studies (Activation Pending)
   a. AFT41: Phase II RID +/- Dara in non-SCT eligible ND MM – Paul Richardson

IV. Endorsed Studies
a. ECOG – E1A11: Phase III RVd vs KRd in ND MM – Edward Faber

b. ECOG – E3A06: Phase III Smoldering Myeloma (lenalidomide vs placebo) – Anuj Mahindra

c. SWOG – S1211: Phase III RVd +/- Elo for ND high risk MM – Peter Voorhees

d. SWOG – S1304: Phase II Carfilzomib in RR MM (completed; results pending) – Peter Voorhees

e. BMT CTN 1302: Phase II RIC Allo-SCT followed by Ixazomib maintenance in NDMM – Cristina Gasparetto

f. SWOG – S1702: Phase II Isatuximab for previously treated AL Amyloidosis – Heather Landau & Hani Hassoun

V. New Initiatives in Process

a. AFT35: Phase I/II PVd Dara in RRMM – Hani Hassoun, Paul Richardson

b. A061901: Phase I/II study of Venetoclax w/ RVD + Dara in newly-diagnosed plasma cell leukemia – Peter Voorhees

c. A061902: Maintenance after 2nd transplant with Venetoclax – Sarah Holstein

d. Rev +/- ACY241 (Citarinostat) S/PASCT– Sarah Holstein

VI. New Proposals in Development

a. Optimal duration of lenalidomide maintenance in MRD negative NDMM patients post ASCT – Peter Voorhees

b. Phase II study of CyBorD-Dara in monoclonal gammopathy-associated kidney diseases – Hani Hassoun, Sasha Tuchman, Anuj Mahindra

c. Phase II study of Venetoclax/dex VS Carfilzomib/Venetoclax/dex in RRMM patients with t(11;14) – Sarah Holstein

d. Selinexor/Carfilzomib/dex in RRMM After Dara-failure – Cristina Gasparetto, Andrew Yee, Paul Richardson

e. Relapsed, Refractory Multiple Myeloma – Treatment Strategies After CAR T Failure – Sarah Holstein
f. Phase I/II study of AMG 701 in RRMM patients post CAR T-Cell relapse – Jens Hillengass

VII. Correlative Science Studies

a. A151210/ A151211: Understanding the molecular basis for myeloid B-cell transformation in the plasma cell dyscrasias and second malignancies in myeloma – Phil McCarthy

b. Therapeutic Subcommittee for MM in Older Adults – Tanya Wildes, Sascha Tuchman, Ashley Rosko

VIII. Closing Remarks